Meiragtx Holdings Plc Form 4 Filings

MeiraGTx Holdings plc CFO & COO Richard Giroux sold 56,000 Ordinary Shares on July 21, 2026 at a $12.51 weighted average price, with individual trades executed between $12.00 and $12.63 per share. The reported price is a weighted average, reflecting multiple sale transactions.

The sales were effected under a Rule 10b5-1 trading plan adopted on November 18, 2025. Following these transactions, Giroux is reported as directly holding 908,530 Ordinary Shares, with additional indirect holdings of 5,152 shares by his spouse and 85,000 shares by Aigle Healthcare Partners III LLC.

MeiraGTx Holdings plc chief scientific officer for ophthalmology Stuart Naylor sold 27,659 ordinary shares of the company in open-market transactions. The sales occurred on July 7, 2026 at weighted average prices reported around $13.36 to $15.33 per share across multiple trades.

Following these transactions, Naylor directly holds 640,846 ordinary shares of MeiraGTx. The filing notes that the sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 9, 2025, indicating the trades were scheduled in advance rather than timed opportunistically.

MeiraGTx Holdings plc granted its Chief Medical Officer, Robert K. Zeldin, 100,000 restricted share units (RSUs). Each RSU converts into one ordinary share upon vesting, so the award represents 100,000 underlying ordinary shares.

According to the vesting schedule, 50% of the RSUs will vest on the second anniversary of the grant date, with an additional 25% vesting on each of the third and fourth anniversaries. Following this grant, Zeldin is reported as holding 100,000 RSUs directly.

MeiraGTx Holdings plc reported that its General Counsel and Secretary, Robert J. Wollin, received a grant of 100,000 restricted share units. Each restricted share unit converts into one ordinary share upon vesting. Half the award vests on the second anniversary of the grant date, with 25% vesting on each of the third and fourth anniversaries.

Naylor Stuart reported acquisition or exercise transactions in this Form 4 filing.

MeiraGTx Holdings plc reported that Chief Scientific Officer of Ophthalmology Stuart Naylor received a grant of 70,000 Restricted Share Units. Each RSU represents the right to receive one ordinary share upon vesting. Half of the award vests on the second anniversary of the grant, with 25% vesting on each of the third and fourth anniversaries.

Giroux Richard reported acquisition or exercise transactions in this Form 4 filing.

MeiraGTx Holdings plc granted its CFO & COO, Richard Giroux, 980,000 restricted share units. Each unit represents the right to receive one ordinary share for no cash payment when it vests.

According to the award terms, 50% of the RSUs vest on the second anniversary of the grant date, with 25% vesting on each of the third and fourth anniversaries.

Forbes Alexandria reported acquisition or exercise transactions in this Form 4 filing.

MeiraGTx Holdings plc reported an equity compensation grant to its President and CEO, Alexandria Forbes. On June 25, 2026, Forbes received 980,000 restricted share units (RSUs), each representing the right to receive one ordinary share for no cash payment upon vesting.

According to the disclosure, fifty percent of this RSU award will vest on the second anniversary of the grant date, with twenty-five percent vesting on each of the third and fourth anniversaries. Following this grant, Forbes holds 980,000 RSUs directly, aligning her compensation with the company’s long-term share performance.

MeiraGTx Holdings plc director Debra Yu received a grant of 60,000 restricted share units (RSUs). These RSUs were awarded as a stock-based compensation grant and each unit will convert into one ordinary share when settled.

The RSUs are scheduled to vest in a single installment on the earlier of June 11, 2027, or the day immediately before MeiraGTx’s 2027 annual shareholder meeting. The reporting person has elected that the RSUs become settleable when she ceases to be a director, so actual share delivery will occur at that time. Following this grant, she holds 60,000 RSUs directly.

SHENK THOMAS E reported acquisition or exercise transactions in this Form 4 filing.

MeiraGTx Holdings plc director Thomas E. Shenk received a grant of 69,662 restricted share units. Each unit represents the right to receive one ordinary share upon settlement. The filing shows he now holds 69,662 restricted share units directly after this award.

The units will vest in a single annual installment on the earlier of June 11, 2027 or the day immediately prior to MeiraGTx’s 2027 annual meeting of shareholders. The reporting person elected to have the restricted share units become settleable when he ceases to be a director.

MeiraGTx Holdings plc director Nicole Seligman received a grant of 60,000 restricted share units (RSUs). The award was made on June 11, 2026 and is a form of equity compensation, not an open‑market share purchase or sale.

Each RSU converts into one ordinary share upon settlement. The RSUs vest in a single installment on the earlier of June 11, 2027 or the day immediately prior to MeiraGTx’s 2027 annual shareholder meeting. Seligman elected to have the RSUs become settleable when she ceases to be a director, and following this grant she holds 60,000 RSUs.

MeiraGTx Holdings plc director Neil Mendoza received a grant of 66,641 restricted share units (RSUs) on June 11, 2026. Each RSU converts into one ordinary share upon settlement. The RSUs vest in a single installment on the earlier of June 11, 2027 or the day immediately prior to MeiraGTx’s 2027 annual shareholder meeting. Mendoza elected to have the RSUs become settleable when he ceases to be a director, and his reported RSU holdings after this grant total 66,641 units.

MeiraGTx Holdings plc director Ellen Hukkelhoven received a grant of 60,000 Restricted Share Units (RSUs). These RSUs were awarded as a compensation-related grant with no cash price per unit and are reported as a derivative security linked to the company’s ordinary shares.

Each RSU converts into one ordinary share upon settlement. According to the terms, the RSUs will vest in a single installment on the earlier of June 11, 2027 or the day immediately before MeiraGTx’s 2027 annual shareholder meeting. The reporting person elected to have the RSUs become settleable when she ceases to be a director.

Harris Keith R. reported acquisition or exercise transactions in this Form 4 filing.

MeiraGTx Holdings plc director Harris Keith R. received a grant of 106,441 restricted share units as equity compensation. Each unit represents the right to receive one ordinary share upon settlement. These restricted share units vest in a single installment on the earlier of June 11, 2027 or the day immediately before the company’s 2027 annual shareholder meeting. Following this grant, Harris holds 106,441 restricted share units directly.

PERCEPTIVE ADVISORS LLC reported acquisition or exercise transactions in this Form 4 filing.

MeiraGTx Holdings plc reported a new equity award to a Perceptive Advisors–related entity tied to board service. Perceptive-affiliated holders received 60,000 restricted share units, each convertible into one ordinary share upon settlement. The units vest in a single installment on the earlier of June 11, 2027 or the day before the company’s 2027 annual shareholder meeting, and become settleable when director Ellen Hukkelhoven leaves the board. The filing notes Perceptive Advisors, its master fund, and Joseph Edelman may be deemed to have only an indirect pecuniary interest and each disclaims beneficial ownership beyond that indirect interest. This is a compensation-related equity grant rather than an open-market purchase or sale.

MeiraGTx Holdings plc director Harris Keith R. exercised equity awards to acquire additional stock. He converted 75,000 restricted share units into 75,000 ordinary shares through an exercise or conversion of a derivative security, with no reported purchase price.

Following this transaction, his direct holdings in ordinary shares increased to 200,000 shares. The related derivative position in these 75,000 restricted share units is now shown as fully converted, reflecting a routine compensation-related equity settlement rather than an open-market trade.

MeiraGTx Holdings plc executive Richard Giroux reported a bona fide gift of company shares. The CFO & COO gifted 7,000 Ordinary Shares at a price of $0.0000 per share and now holds 964,530 Ordinary Shares directly. He also reports indirect ownership of 85,000 Ordinary Shares through Aigle Healthcare Partners III LLC and 5,152 Ordinary Shares held by his spouse.

MeiraGTx Holdings plc President & CEO Alexandria Forbes reported an open-market sale of 62,000 Ordinary Shares on May 19, 2026 at a weighted average price of $9.17 per share. The shares were sold in multiple trades between $8.96 and $9.32.

After this transaction, Forbes directly holds 1,387,695 Ordinary Shares. The sale was carried out under a Rule 10b5-1 trading plan that was adopted in advance, indicating the trades were pre-scheduled rather than opportunistic.

MeiraGTx Holdings plc chief development officer Penny Renee Fleck reported compensation-related equity grants. She received 100,000 restricted share units, each convertible into one ordinary share upon vesting, and a stock option for 100,000 ordinary shares at an exercise price of $9.97 per share, vesting over several years with final option expiration on May 1, 2036.

MeiraGTx Holdings plc Chief Medical Officer Robert K. Zeldin reported an administrative update related to equity compensation. On the vesting of an award, 7,814 Ordinary Shares were withheld to pay taxes at an indicated value of $7.73 per share. Following this tax-withholding disposition, he beneficially owns 146,204 Ordinary Shares directly. This amended filing corrects the previously reported number of shares withheld and the post-transaction holdings, and also adjusts total beneficial ownership down by two shares to address earlier rounding errors.

MeiraGTx Holdings plc reported that investment entities associated with Perceptive Advisors adjusted their equity and warrant positions. Perceptive Life Sciences Master Fund Ltd. now indirectly holds 10,786,658 Ordinary Shares after receiving a grant of 555,555 shares at $9.00 per share on April 17, 2026.

On March 25, 2026, Perceptive Credit Holdings III, LP received two warrant grants covering 300,000 and 400,000 Ordinary Shares at an $8.00 exercise price, expiring on August 2, 2027. On the same date, earlier warrants for 300,000 shares at $20.00 and 400,000 shares at $15.00 were disposed of back to the issuer under a financing agreement adjustment.

MeiraGTx Holdings plc CFO & COO Richard Giroux reported an open-market sale of 56,000 Ordinary Shares at a weighted average price of $10.22 per share. The sale was executed as a single economic event across multiple trades at prices ranging from $9.96 to $10.60.

Following this transaction, Giroux directly holds 971,530 Ordinary Shares. He also reports indirect ownership of 85,000 shares through Aigle Healthcare Partners III LLC and 5,152 shares held by his spouse. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2025.

MeiraGTx Holdings plc chief development officer Stuart Naylor reported an open-market sale of 27,661 Ordinary Shares of MGTX on April 7, 2026. The shares were sold at a weighted average price of $9.36, in multiple trades between $9.11 and $9.52 per share.

After this transaction, Naylor directly holds 668,505 Ordinary Shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 9, 2025, indicating it was planned in advance rather than timed discretionarily.

MeiraGTx Holdings plc’s President and CEO Alexandria Forbes reported an open-market sale of 62,000 Ordinary Shares of MGTX. The shares were sold at a weighted average price of $7.41 per share in multiple transactions between $7.27 and $7.56.

The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Following these sales, Forbes directly holds 1,449,695 Ordinary Shares of MeiraGTx.

MeiraGTx Holdings plc chief medical officer Robert K. Zeldin reported equity award activity involving restricted share units and ordinary shares. On February 21, 2026, one quarter of a restricted share unit grant from February 21, 2023 vested, converting 7,500 restricted share units into 7,500 ordinary shares at no cash exercise price. In connection with this vesting, 2,952 ordinary shares were automatically withheld at a price of $7.45 per share to cover tax obligations, a tax-withholding disposition rather than an open-market sale. After these transactions, Zeldin directly held 172,888 ordinary shares.

MeiraGTx Holdings plc reported that its General Counsel and Secretary, Robert J. Wollin, acquired ordinary shares through the vesting of restricted share units. On February 21, 2026, one-quarter of a prior grant of 11,250 restricted share units vested and converted into 11,250 ordinary shares at no exercise price.

Following the conversion, 5,949 ordinary shares were withheld to cover tax obligations associated with the vesting, at a price of $7.45 per share. After these transactions, Wollin held 57,377 ordinary shares directly. These movements reflect routine equity compensation vesting and related tax withholding rather than open‑market trading.

MeiraGTx Holdings plc Chief Development Officer Stuart Naylor reported equity award activity related to previously granted restricted share units. On February 21, 2026, one-quarter of his restricted share units granted on February 21, 2023 vested, resulting in 25,000 restricted share units converting into 25,000 ordinary shares, with no exercise price. Following this vesting and conversion, his direct holdings briefly totaled 707,916 ordinary shares. To cover tax obligations on the vesting, 11,750 ordinary shares were withheld and disposed of at $7.45 per share, a tax-withholding disposition rather than an open-market sale, leaving him with 696,166 ordinary shares held directly.

MeiraGTx Holdings plc CFO & COO Richard Giroux reported equity award activity involving restricted share units and ordinary shares. On February 21, 2026, one-quarter of previously granted restricted share units vested, converting 60,000 restricted share units into 60,000 ordinary shares at a stated price of $0.00 per share. To cover taxes due upon vesting, 31,726 ordinary shares were withheld at $7.45 per share as a tax-withholding disposition. Following these transactions, Giroux directly held 1,027,530 ordinary shares, with additional indirect holdings of 5,152 ordinary shares held by his spouse and 85,000 ordinary shares held by Aigle Healthcare Partners III LLC.

MeiraGTx Holdings plc President and CEO Alexandria Forbes reported equity award activity involving restricted share units and ordinary shares. On February 21, 2026, 62,500 restricted share units vested and were converted into 62,500 ordinary shares at a stated price of $0.0000 per share. A separate entry shows 33,048 ordinary shares withheld at $7.45 per share to cover taxes due upon vesting of the award, rather than an open-market sale. Following these transactions, Forbes directly holds 1,511,695 ordinary shares of MeiraGTx.

MeiraGTx Holdings plc’s Chief Medical Officer, Robert K. Zeldin, reported equity compensation activity on January 17, 2026. One-half of a prior grant of restricted share units vested, resulting in 35,000 restricted share units converting into the same number of ordinary shares at an exercise price of $0.

To cover taxes due on this vesting, 13,951 ordinary shares were automatically withheld and disposed of at a price of $7.42 per share. After these transactions, Zeldin directly beneficially owned 168,340 ordinary shares of MeiraGTx. The filing indicates these are routine equity award vesting and tax-withholding events rather than open-market purchases or discretionary sales.

MeiraGTx Holdings plc reported an insider equity transaction for its General Counsel and Secretary, Robert J. Wollin. On January 17, 2026, one-half of a prior award of restricted share units vested, resulting in 50,000 ordinary shares being issued upon conversion of the vested units at an exercise price of $0 per share. In a related transaction, 27,206 ordinary shares were withheld at $7.42 per share to cover taxes due on the vesting. Following these transactions, Wollin directly owned 52,076 ordinary shares of MeiraGTx.

MeiraGTx Holdings plc Chief Development Officer Stuart Naylor reported equity compensation activity on January 17, 2026. One-half of a prior grant of restricted share units vested, converting 75,000 restricted share units into 75,000 ordinary shares at an exercise price of $0. To cover taxes due upon vesting, 35,250 ordinary shares were withheld at a value of $7.42 per share. After these transactions, Naylor directly owned 682,916 ordinary shares of MeiraGTx and continued to hold 75,000 restricted share units that remain outstanding.

MeiraGTx Holdings plc officer reports RSU vesting and related share withholding. On January 17, 2026, CFO & COO Richard Giroux had 310,000 restricted share units vest, each converting into one ordinary share at an exercise price of $0. In a separate transaction the same day, 163,916 ordinary shares were disposed of at $7.42 per share to cover taxes due upon vesting. Following these transactions, Giroux directly beneficially owned 999,256 ordinary shares, with additional indirect holdings of 5,152 shares through a spouse and 85,000 shares through Aigle Healthcare Partners III LLC.

MeiraGTx Holdings plc insider Alexandria Forbes, the President and CEO, reported equity award vesting and related tax withholding. On January 17, 2026, 310,000 restricted share units vested from a grant originally made on January 17, 2024, with each unit converting into one ordinary share upon vesting.

To cover taxes on this vesting, 163,916 ordinary shares were withheld at a price of $7.42 per share. After these transactions, Forbes directly holds 1,482,243 ordinary shares of MeiraGTx and 310,000 restricted share units as derivative securities.

MeiraGTx Holdings plc Chief Medical Officer Robert K. Zeldin filed a Form 4 showing routine equity compensation activity. On January 7, 2026, 17,500 restricted share units granted on January 7, 2022 vested, with each unit converting into one ordinary share. To cover taxes on this vesting, 6,729 ordinary shares were withheld at a price of $7.73 per share rather than being sold in the open market.

After these transactions, Zeldin directly beneficially owned 147,291 ordinary shares of MeiraGTx. The filing reflects compensation-related vesting and associated tax withholding rather than discretionary market buying or selling.

MeiraGTx Holdings plc’s general counsel and secretary, Robert J. Wollin, reported routine equity award activity involving the company’s ordinary shares. On January 7, 2026, one quarter of his restricted share units granted on January 7, 2022 vested, converting 7,500 restricted share units into 7,500 ordinary shares at an exercise price of $0. In connection with this vesting, 4,364 ordinary shares were withheld at a price of $7.73 per share to cover tax obligations. After these transactions, he directly beneficially owned 29,282 ordinary shares of MeiraGTx.

MeiraGTx Holdings plc’s Chief Development Officer Stuart Naylor reported routine equity award activity involving restricted share units and ordinary shares. On January 7, 2026, 37,500 restricted share units vested and converted into the same number of ordinary shares, reflecting one-quarter of an award granted on January 7, 2022. Each restricted share unit converts into one ordinary share upon vesting. To cover tax withholding on this vesting, 17,625 ordinary shares were withheld at a price of $7.73 per share. After these transactions, Naylor directly held 643,166 ordinary shares of MeiraGTx Holdings plc.

MeiraGTx Holdings plc CFO & COO Richard Giroux reported equity compensation activity involving the company’s ordinary shares. On January 7, 2026, 52,500 restricted share units vested, with each unit converting into one ordinary share. As part of the vesting, 28,822 ordinary shares were withheld at a price of $7.73 per share to cover taxes on the award. Following these transactions, Giroux directly beneficially owned 853,172 ordinary shares of MeiraGTx.

MeiraGTx Holdings plc President & CEO and director Alexandria Forbes reported equity award activity in a Form 4. On January 7, 2026, one-quarter of a prior grant of restricted share units vested, converting 62,500 restricted share units granted on January 7, 2022 into the same number of ordinary shares on a one-for-one basis. To cover tax obligations on this vesting, 34,074 ordinary shares were withheld at a price of $7.73 per share. Following these transactions, Forbes directly beneficially owns 1,336,159 ordinary shares of MeiraGTx.

MeiraGTx Holdings plc (MGTX) reported an insider equity transfer by its General Counsel and Secretary. On 11/20/2025, the officer disposed of 5,000 ordinary shares in a transaction reported at a price of $0, using transaction code "G," which indicates a gift. After this transaction, the reporting person directly beneficially owned 26,146 ordinary shares. This filing reflects a change in the insider’s personal holdings and does not describe any operational or financial developments at the company.

MeiraGTx Holdings plc (MGTX) reported an insider transaction: CFO & COO Richard Giroux sold 24,000 ordinary shares on Oct 21, 2025 at a $8.87 weighted average pursuant to a Rule 10b5-1 trading plan adopted Aug 29, 2024.

Sale prices ranged from $8.65 to $9.06. After the transaction, he beneficially owns 829,494 shares directly, plus 5,152 indirectly via spouse and 85,000 indirectly via Aigle Healthcare Partners III LLC.

Insider sale by a senior officer: Alexandria Forbes, listed as President & CEO and a director, reported a sale of 47,500 ordinary shares of MeiraGTx Holdings plc (MGTX) on 10/07/2025. The sales were executed under a pre-established Rule 10b5-1 trading plan adopted on 08/21/2024.

The filing shows a weighted average sales price of $8.39, with individual trade prices ranging from $8.23 to $8.53. Following the reported disposition, the reporting person beneficially owns 1,313,983 ordinary shares.